ssm 2171 Improving IV Medication Safety.qxd
1 Of all the medication errors, intravenous (IV) infusion errors, which involve high- risk medications delivered directly into a patient's bloodstream, have the greatest potential for patient harm. This index is used to categorize errors that have actually occurred and where the patient's condition is known. Using the above criteria and conservative estimates of the potential...
author: gbon
ssm 2171 Improving IV Medication Safety.qxd page 6
author: gbon
Generic Names of Some Trade Name Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs -~ Generic Names of Some Trade Name Drugs - Generic Names of Some...
Some Trade Names of Generic Drugs, THE MERCK MANUAL OF HEALTH & AGING
Committed to Providing Medical Information Table of Contents Index Enlarge Text Reset Text Shrink Text -- Buy the Book Learn about participating in clinical trials at this government website: www.clinicaltrials.gov - APPENDIX I - Drug Names: Generic and Trade TOPICS - Introduction -~ Some Trade Names of Generic Drugs-~ Generic Names of Some Trade Name Drugs - Some Trade Names of...
Peptic Ulcer: Peptic Disorders: Merck Manual Home Edition
Drugs Used to Treat Peptic Disorders Type Drug Selected Side Effects Comments Antacids - Aluminum hydroxide Calcium carbonate Magnesium hydroxide Sodium bicarbonate Nausea, headache, weakness, loss of appetite, constipation (aluminum hydroxide) or diarrhea (magnesium hydroxide) Used mainly to relieve symptoms, not as a cure Histamine-2 blockers - Cimetidine Famotidine Nizatidine...
Peptic Ulcer: Peptic Disorders: Merck Manual Home Edition
Drugs Used to Treat Peptic Disorders Type Drug Selected Side Effects Comments Antacids - Aluminum hydroxide Calcium carbonate Magnesium hydroxide Sodium bicarbonate Nausea, headache, weakness, loss of appetite, constipation (aluminum hydroxide) or diarrhea (magnesium hydroxide) Used mainly to relieve symptoms, not as a cure Histamine-2 blockers - Cimetidine Famotidine Nizatidine...
Index: PA: Merck Manual Home Edition
Search Recent Searches Index Sections A B C D E F G H I J K L M N O P Q R S T U V W X Y Z Accidents and Injuries Blood Disorders Bone, Joint, and Muscle Disorders Brain, Spinal Cord, and Nerve Disorders Cancer Children's Health Issues Digestive Disorders Disorders of Nutrition and Metabolism Drugs Ear, Nose, and Throat Disorders Eye Disorders Fundamentals Heart and Blood Vessel...
Wyeth: News & Announcements
Back to my archive search Start a new archive search 02/02/2000 FDA Approves Tablet Formulation of Protonix® (Pantoprazole Sodium) A New Proton Pump Inhibitor For The Treatment Of Erosive Esophagitis Madison, N.J., February 2, 2000 - American Home Products Corporation (NYSE:AHP) announced today that Protonix® (pantoprazole sodium) Delayed-Release tablets has been...
Wyeth: News & Announcements
Back to my archive search Start a new archive search 05/17/2000 Now Available - Protonix® (Pantoprazole Sodium) for the Short-Term Treatment of Erosive Gerd and Associated Symptoms, Including Nighttime Heartburn Short-Term Treatment of Erosive Gerd and Associated Symptoms, Including Nighttime Heartburn Priced Significantly Less Per Day Than The Leading Medication Madison, N...
Wyeth: News & Announcements
Back to my archive search Start a new archive search 03/23/2001 FDA APPROVES NEW I.V. (PANTOPRAZOLE SODIUM) FOR INJECTION BECOMES FIRST PPI AVAILABLE IN THE U.S. for Injection as an initial treatment for GERD have not been demonstrated. and PROTONIX® I.V. and an oral formulation that has not exhibited evidence of tolerance (loss of efficacy).- PROTONIX®...
Wyeth: News & Announcements
Back to my archive search Start a new archive search 06/14/2001 FDA EXPANDS INDICATION FOR PROTONIX® (PANTOPRAZOLE SODIUM) DELAYED-RELEASE TABLETS Long-term Management of Nighttime and Daytime Heartburn Symptoms with Maintenance Therapy of Healing in GERD Patients Long-term Management of Nighttime and Daytime Heartburn Symptoms with Maintenance Therapy of Healing in GERD...
Wyeth: News & Announcements
Back to my archive search Start a new archive search 10/22/2001 PROTONIX® I.V. (PANTOPRAZOLE SODIUM) RECEIVES EXPEDITED APPROVAL FROM FDA TO TREAT ZOLLINGER-ELLISON SYNDROME I.V. Food and Drug Administration (FDA) for the treatment of pathological hypersecretory conditions associated with Zollinger-Ellison Syndrome or other neoplastic conditions. is marketed in...
Wyeth: News & Announcements
Back to my archive search Start a new archive search 05/03/2002 ProtonixA® (PANTOPRAZOLE SODIUM) Delayed-Release Tablets Approved for Long-Term Treatment of Zollinger-Ellison Syndrome First and Only PPI with IV and Oral Formulations Approved to Treat This Serious Acid-Related Disease Madison, N.J., May 3, 2002 - Wyeth (NYSE: WYE) announced that PROTONIXA®A- ...
Wyeth: News & Announcements
Carrion to the Board of Directors July 20, 2000 Second Quarter 2000 Earnings July 20, 2000 American Home Products Corporation Declares Common Stock Dividend July 20, 2000 American Home Products Corporation Announces Executive Promotions and Organizational Changes July 17, 2000 Wyeth-Ayerst's Effexor-XR® Receives New Label Change for Long-Term Treatment of Generalized Anxiety...
Wyeth: News & Announcements
(PANTOPRAZOLE SODIUM) RECEIVES EXPEDITED APPROVAL FROM FDA TO TREAT ZOLLINGER-ELLISON SYNDROME October 19, 2001 American Home Products Corporation Sets Webcast and Analyst Call For Quarterly Earnings October 10, 2001 MAJOR PUBLIC HEALTH CAMPAIGN SEEKS TO REMOVE BARRIERS TO DIAGNOSIS, TREATMENT OF DEPRESSION October 09, 2001 AHP Selected as One of Working Mother Magazine's 100...
Wyeth: News & Announcements
AS SENIOR VICE PRESIDENT, WYETH AND PRESIDENT, WYETH RESEARCH June 20, 2002 WYETH DECLARES PREFERRED STOCK DIVIDEND June 20, 2002 WYETH DECLARES COMMON STOCK DIVIDEND June 20, 2002 WYETH ANNOUNCES EXECUTIVE PROMOTIONS AND ORGANIZATIONAL CHANGES June 10, 2002 WYETH DISCONTINUES CLINICAL PROGRAM FOR ITS TYPE-2 DIABETES CANDIDATE June 10, 2002 Wyeth Announces the Sale of its ESI Lederle...
Proton pump inhibitors for gastroesophageal reflux disease (GERD) - [Medication] - Quest Diagnostics Patient Health Library
Proton pump inhibitors for gastroesophageal reflux disease (GERD) Examples Brand Name Chemical Name Nexium esomeprazole Prevacid lansoprazole Prilosec omeprazole Protonix pantoprazole Aciphex rabeprazole These medications are available as time-release capsules that are taken orally once a day.Pantoprazole (Protonix) can also be given intravenously (IV). This allows the...
Possible anti-cancer activity of proton pump inhibitors - new indications may lead to market advantage within a highly
- - - - BioNews BioWeb Companies Products BioReports - - - - - Channels Select Channel -------> Channels Home Page BioWeb Search BioNews Search BioNews Topics BioWatch Tracking BioJob Career Bio/Pharma Events BioNewsCast BioCorporate BioReports Indication/Disease BioZak CD-rom BioTechnologies BioExecutive BioEquities/Stocks BioDrug Discovery BioJournal BioAnalysis BioSuppliers...
http://www.solvo.hu/Scienceletter/1/CindyXia-BCRP-DrivingDMPK-Philadelphia2005.pdf
Interactions of MTX with Pantoprazole in Mice Fecal and urinary excretion of [ 3 H] MTX in mice pretreated with pantoprazole or NaCl 0.9% (control). DMD 33: 637 (2005) BCRP and P- gp Mediated the Efflux of MLNXYZ in Caco- 2 Cells P app x10 6 (cm/ sec) of MLNXYZ +LY335979 5 µM 0 5 10 15 20 25 MLNXYZ µg/ ml +Ko143 1 µM +MK571 50 µ M +GF120918 2 µM...
AstraZeneca Annual Business Review 2001-Row Presentation
Realising the value RoW: Bruno Angelici A A Bruno Angelici A Markets outside North America are performing strongly Latin America Sales $485m Source : MAT sales October 2001 internal data Europe Sales $4933m Japan Sales $839m Asia Pacific Sales $674m Realising the value RoW: Bruno Angelici A A Focus on Europe & Japan b 2001 performance building a strong platform for growth b...
BioPortfolio Limited
The Gastrointestinal Market 2003: New Blockbusters and Competitive Dynamics 1 Gastrointestinal Conditions 1.1 An Introduction to Gastrointestinal Conditions 1.2 Report Objectives 1.3 Worldwide Impact of Gastrointestinal Conditions 1.3.1 Demographic Prevalence Graph 1.1 Percentage of Hospitalizations Due to Gastrointestinal Causes Graph 1.2 Percentage of Diagnostic and Therapeutic...
Specificity Table TOX.xls
Tested (ng/ ml) Previcid Lansoprazole Anti- ulcerative 100,000 Prilosec Omeprazole Anti- ulcerative 100,000 Primacor Milrinone Cardiotonic 100,000 Primaquine Primaquine Antimalarial 100,000 Prinivil Lisinopril Antihypertensive 100,000 Proaqua Benzthiazide Diuretic 100,000 Proasma Methoxyphenamine Bronchodilator 100,000 Procardia Nifedipine Antianginal 100,000 Prolixin Fluphenazine...
author: Biosite Incorporated
Specificity Table TOX.xls page 22
author: Biosite Incorporated
http://www.adis.com/files/newsletters/INP/Icov1438.pdf
20 Human skin replacement heals venous leg ulcers 8 Dexketoprofen trometamol for dental pain 9 Imiquimod cream "promising" for Bowen's disease 15 Opioid analgesic prescribing highly variable 7 Paclitaxel: useful treatment for severe psoriasis 9 Paroxetine controlled- release: benefits in fibromyalgia 11 Rofecoxib for postoperative dental pain 9 ENDOCRINOLOGY Alendronic acid vs...
http://www.adis.com/files/newsletters/REA/Rxcov999.pdf
16 Capecitabine: coronary spasm [S] 7 Pharmacovigilance & Regulatory News Carbamazepine: skin rash, fever, eosinophilia and systemic 7 Leflunomide and zonisamide safety information updated in 2 symptoms [S] Japan Cefazolin: photo recall eruption 8 Zonisamide and leflunomide safety information updated in 2 Cefepime: anaphylaxis [ S] 8 Japan Citalopram: hypertension [ ] 8 2002 ADR...